The Board of Directors of the Company at its meeting held on August 01, 2025, has, inter alia, considered and approved the Unaudited Financial Results of the Company (Standalone andConsolidated), for the quarter ended June 30, 2025
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
HCG reported Q1 FY26 standalone revenue from operations of Rs. 32,593 lakhs (up ~3.9% from Rs. 31,360 lakhs in restated Q1 FY25), but profit before tax fell sharply to Rs. 179 lakhs from Rs. 1,276 lakhs, and the company recorded a net loss of about Rs. 206 lakhs after a tax outflow of Rs. 385 lakhs. Consolidated revenue grew ~16.6% to Rs. 61,180 lakhs, but consolidated PAT dropped to Rs. 598 lakhs (from Rs. 1,363 lakhs) and EPS fell to Rs. 0.34 from Rs. 0.87. The quarter included an exceptional loss of Rs. 155 lakhs and Rs. 157 lakhs in legal/professional fees for the KKR share purchase. Prior-year Q1 figures were restated to reflect a common-control business transfer with HCG NCHRI Oncology LLP.
Weak operating quarter with margin compression and a standalone net loss, partly dragged by exceptional items and one-off transaction costs. Shareholders have a near-term price reference of Rs. 504.41 per share from the KKR-led mandatory open offer, while a major ownership shift to KKR (51.59% acquired on May 30, 2025) and Rs. 5,808 lakhs cash ESOP settlement could pressure near-term earnings but may improve long-term strategic direction.